<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03489876</url>
  </required_header>
  <id_info>
    <org_study_id>SynCartImp_Amin</org_study_id>
    <nct_id>NCT03489876</nct_id>
  </id_info>
  <brief_title>Synthetic Cartilage Implant vs Osteochondral Autograft Transfer for Advanced 1st Metatarsal Phalangeal Joint Arthritis</brief_title>
  <official_title>Comparison of Synthetic Cartilage Implant Versus Osteochondral Autologous Transfer for Advanced Hallux Rigidus, A Prospective Randomized Controlled Clinical Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Oklahoma</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of Oklahoma</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>Yes</is_fda_regulated_device>
    <is_unapproved_device>No</is_unapproved_device>
    <is_ppsd>No</is_ppsd>
    <is_us_export>Yes</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a prospective, randomized, controlled clinical trial comparing synthetic cartilage
      implantation versus osteochondral autograft transfer for treatment of first
      metatarsophalangeal (MTP) arthritis. This data will allow for accurate comparisons between
      the two groups in regards to functional outcome, clinical outcome, pain relief, and
      complications.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      First MTP joint arthritis or hallux rigidus is the most common arthritic condition of the
      foot. Historically, there have been several options to treat this condition surgically, but
      the current standard for advanced hallux rigidus is first MTP anthrodesis. Newer joint
      preserving procedures offer patients effective relief of pain and improving functional
      outcomes as well as maintaining, and potentially improving, range of motion for the first MTP
      joint. Osteochondral autograft transfer has been shown to be an effective treatment for
      hallux rigidus, and involves harvesting a small cylindrical osteochondral graft from a site
      remote of the first MTP joint and transferring the graft to the head of the first metatarsal.
      A new synthetic cartilage implant, Cartiva, has been shown to have equivalent functional
      outcomes, pain scores, and complications to anthrodesis, but the first MTP range of motion in
      the Cartiva group was maintained or even improved in some patients.

      This is a prospective, randomized, controlled clinical trial comparing synthetic cartilage
      implantation versus osteochondral autograft transfer for treatment of first
      metatarsophalangeal (MTP) arthritis. The hypothesis is that clinical range of motion, pain
      scores, subjective clinical outcomes, and complications will not be clinically inferior with
      the synthetic cartilage implant group compared to the osteochondral autograft transfer group.
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">July 1, 2018</start_date>
  <completion_date type="Anticipated">December 2025</completion_date>
  <primary_completion_date type="Anticipated">December 2023</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>Upon eligibility verification and informed consent, computer-based randomization will allot patients into one of the two treatment groups, either synthetic cartilage implant or osteochondral autograft transfer.</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
    <masking_description>The computer-based randomization sequence will be concealed from investigators using REDCap.</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>Range of Motion</measure>
    <time_frame>2 years</time_frame>
    <description>Pre-operative and post-operative clinical range of motion of the first MTP joint</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Pain</measure>
    <time_frame>2 years</time_frame>
    <description>Pre-operative and post-operative visual analog pain scale</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Quality of Life</measure>
    <time_frame>2 years</time_frame>
    <description>Foot and Ankle Ability Measure (FAAM) sports score uses patient-report to determine function</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Clinically-Assessed Foot and Ankle Function</measure>
    <time_frame>2 years</time_frame>
    <description>American Orthopedic Foot and Ankle Score (AOFAS) Hallux Metatarsophalangeal-Interphalangeal Scale</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Health Status</measure>
    <time_frame>2 years</time_frame>
    <description>12-item short form health survey, use of concomitant medications, and changes in health status</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Surgical Complications</measure>
    <time_frame>2 years</time_frame>
    <description>Fractures, nerve injuries, blood loss, infection, etc.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Implant Failure</measure>
    <time_frame>2 years</time_frame>
    <description>Failure of the Cartiva Synthetic Cartilage Implant</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Secondary Surgical Intervention</measure>
    <time_frame>2 years</time_frame>
    <description>Additional subsequent procedures, including removal, reoperation, revision, or supplemental fixation</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">300</enrollment>
  <condition>Metatarsophalangeal Joint Arthritis</condition>
  <arm_group>
    <arm_group_label>Synthetic Cartilage Implant</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants receive the synthetic cartilage implant. The synthetic cartilage implant that will be used is the Cartiva implant.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Osteochondral Autograft Transfer</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Participants receive the current standard osteochondral autograft transfer procedure.</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Synthetic Cartilage Implant</intervention_name>
    <description>The Synthetic Cartilage Implant will be implanted in to the first metatarsal head according to the manufacturer's recommendations.</description>
    <arm_group_label>Synthetic Cartilage Implant</arm_group_label>
    <other_name>Cartiva</other_name>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Osteochondral Autograft Transfer</intervention_name>
    <description>The osteochondral autograft transfer will be harvested from the ipsilateral lateral femoral condyle (or contralateral if a previous ipsilateral total knee anthroplasty or trauma) and the graft will be transferred to the first metatarsal head.</description>
    <arm_group_label>Osteochondral Autograft Transfer</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Between the ages of 18 and 80 years old

          -  Grade 2 or 3 hallux rigidus based on Coughlin and Shurnas classification

          -  Presence of good bone stock as determined on pre-operative x-rays not requiring bone
             grafting

          -  Capable of consenting for self

        Exclusion Criteria:

          -  Patients &lt;18 years of age

          -  Grade 1 or 4 hallux rigidus based on Coughlin and Shurnas classification

          -  Active bacterial infection of the foot

          -  Previous bilateral total knee arthroplasty

          -  Previous fracture or significant trauma to the ipsilateral knee

          -  Inflammatory anthropathy

          -  Gout

          -  Inadequate bone stock

          -  Previous anthrodesis or arthroplasty performed on the ipsilateral first MTP
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Amgad Amin, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Department of Orthopedic Surgery and Rehabilitation</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Siri A Ogg, MS</last_name>
    <phone>405-271-4426</phone>
    <phone_ext>47977</phone_ext>
    <email>siri-ogg@ouhsc.edu</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Janet M Wells, RN</last_name>
    <phone>405-271-4426</phone>
    <phone_ext>47939</phone_ext>
    <email>janet-wells@ouhsc.edu</email>
  </overall_contact_backup>
  <verification_date>May 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>March 19, 2018</study_first_submitted>
  <study_first_submitted_qc>March 29, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">April 6, 2018</study_first_posted>
  <last_update_submitted>May 23, 2018</last_update_submitted>
  <last_update_submitted_qc>May 23, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">May 25, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Metatarsophalangeal Joint</keyword>
  <keyword>Arthritis</keyword>
  <keyword>Synthetic Cartilage Implant</keyword>
  <keyword>Cartiva</keyword>
  <keyword>Osteochondral Autograft Transfer</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Arthritis</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

